Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Michael Mendelsohn
Age : 65
Public asset : 8,280 USD
Country of residence : Unknown
Linked companies : Takeda Pharmaceutical Company Limited - Foghorn Therapeutics Inc. - Cyclerion Therapeutics, Inc.

Biography of Michael Mendelsohn 
Dr. Michael E. Mendelsohn, MD, is an Independent Director at Cyclerion Therapeutics, Inc., an Independent Director at Foghorn Therapeutics, Inc., a Chairman at Cardurion Pharmaceuticals LLC, a Chief Medical & Scientific Officer at Takeda Pharmaceutical Co., Ltd. and a President at Mendelsohn Consulting Group LLC. He is on the Board of Directors at Cyclerion Therapeutics, Inc. and Foghorn Therapeutics, Inc. Dr. Mendelsohn was previously employed as a President & Chief Scientific Officer by Ironwood Pharmaceuticals, Inc., a Venture Partner by SV Life Sciences Managers LLP, an Independent Director by Regado Biosciences, Inc., a Senior VP & Global Head-Cardiovascular Research by Merck Research Laboratories Massachusetts LLC, an Executive Director-MCRI by Tufts Medical Center, Inc., and a Chief Scientific Officer by Tufts University School of Medicine. He received his undergraduate degree from Amherst College and a doctorate degree from Harvard Medical School.


Current positions of Michael Mendelsohn 
Holdings of Michael Mendelsohn 
Michael Mendelsohn : Personal Network 
Most Read News 
09/22WILLIAM ACKMAN : Ackman's Pershing Square fund surges as Universal soars in stock debut
RE
09/14BRAD SMITH : Microsoft to buy back up to $60 billion in shares; names Brad Smith vice chair
RE
09/09FRANCESCO GAETANO CALTAGIRONE : Italy's Caltagirone ups Generali stake to just over 6%
RE
09/14CATHIE WOOD : ARK Invest's Wood expects market rotation back to growth stocks
RE
09/13MARTIN SORRELL : Sorrell's S4 Capital raises annual profit outlook for a third time
RE
09/09ELON MUSK : Tesla's Musk asks staff to 'go super hardcore' to ensure decent Q3 delivery number
RE
09/22CATHIE WOOD : ARK's Cathie Wood says Wall Street not in a bubble
RE
09/21JEFF BEZOS : UK's Johnson discussed taxation with Amazon's Bezos
RE
09/17STELIOS HAJI-IOANNOU : EasyJet shareholder Stelios Haji-Ioannou shuns rights issue -source
RE
09/15JARED ISAACMAN : Stock Futures Tick Up After Market Pullback
DJ
More news


© 2021 People and Ownership :   
Michael Mendelsohn : Connections 


Latest news about Michael Mendelsohn 
2019Cyclerion Therapeutics, Inc. Announces Executive Changes
CI
2019The Board of Directors of Ironwood Pharmaceuticals, Inc. completed the spin-off of Cyclerion Therapeutics, Inc.
CI
2018The Board of Directors of Ironwood Pharmaceuticals, Inc. announced the spin-off of soluble guanylate cyclase business.
CI
More news